Wall Street brokerages expect that Tricida Inc (NASDAQ:TCDA) will report ($0.89) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tricida’s earnings, with the lowest EPS estimate coming in at ($0.91) and the highest estimate coming in at ($0.87). The business is scheduled to announce its next earnings results on Thursday, February 14th.
On average, analysts expect that Tricida will report full-year earnings of ($2.92) per share for the current financial year, with EPS estimates ranging from ($2.94) to ($2.90). For the next financial year, analysts anticipate that the business will post earnings of ($3.45) per share, with EPS estimates ranging from ($3.50) to ($3.39). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Tricida.
A number of research analysts recently weighed in on TCDA shares. Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Thursday, January 10th. Cowen reaffirmed a “buy” rating on shares of Tricida in a research note on Friday, November 9th.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TCDA. Vanguard Group Inc purchased a new position in Tricida in the 3rd quarter worth approximately $33,317,000. Vanguard Group Inc. purchased a new position in Tricida in the 3rd quarter worth approximately $33,317,000. BlackRock Inc. lifted its stake in Tricida by 216.4% in the 3rd quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock worth $30,707,000 after purchasing an additional 687,414 shares in the last quarter. VHCP Management III LLC purchased a new position in Tricida in the 3rd quarter worth approximately $19,875,000. Finally, Millennium Management LLC purchased a new position in Tricida in the 2nd quarter worth approximately $8,766,000. 68.44% of the stock is currently owned by institutional investors and hedge funds.
Tricida stock traded up $0.38 during midday trading on Wednesday, reaching $22.56. The company had a trading volume of 49,800 shares, compared to its average volume of 155,223. Tricida has a 12-month low of $19.43 and a 12-month high of $40.10. The company has a quick ratio of 12.68, a current ratio of 12.68 and a debt-to-equity ratio of 0.11.
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Recommended Story: Buyback For Investors Defined
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.